When neurons die during development, they die by apoptosis, which is characterized by nuclear and chromatin condensation, DNA fragmentation, and the development of "apoptotic bodies." 2, 3, 36, 61 This is an active process that requires both gene transcription and protein synthesis. 46, 57 In contrast, necrotic cell death most often results from the loss of cellular homeostasis. A total depletion of cellular energy (adenosine 5Ј-triphosphate) produces changes in membrane permeability, with the influx of sodium and the loss of potassium, leading to swelling of cytoplasmic compartments and destruction of organelles. There is decreased gene transcription and protein synthesis. 17, 51 Because of the powerful antiapoptotic effects, neurotrophins have potential as therapeutic agents. 4, 5, 13, 16, 41, 42, 45, 52, 54, 56, 57 Following injury, the expression of both NGF and the Trk receptors are upregulated, indicating that they may play a role in endogenous neuroprotection and repair. 26 It is not known whether neurotrophin treatment can decrease necrotic cell death or which receptor subtype is required for action, however. To find the answers to such questions, we used an in vitro model of neuronal injury with the aid of primary cultures from cortices of embryonic rats and an injury paradigm involving hypoxia (oxygen deprivation), ischemia (oxygen-glucose deprivation), or ionizing radiation. 14, 29 (Although termed "ischemia," this in vitro situation does not approximate the complex in vivo situation that occurs during ischemic stroke. Because it deprives the cells of both oxygen and glucose and it produces necrotic cell death, however, the word "ischemia" is accepted in the literature for this form of in vitro injury.) Depending on the noxious stimuli, injured neurons died by apoptosis only, necrosis only, or a combination of the two (as characterized by multiple measures). We then tested the effect of neurotrophin treatment on apoptosis and necrosis and characterized the receptor(s) that were required.
Materials and Methods

Chemicals and Reagents
The tissue culture media and reagents (DMEM, neurobasal medium, B-27 supplements, bovine serum albumin, HBSS, PBS, HEPES, glutamine, penicillin-streptomycin, and so forth) were purchased from Gibco-BRL (Grand Island, NY). The pregnant Sprague-Dawley rats were obtained from Charles River (Wilmington, MA). The cytotoxicity detection kit (LDH) was from Boehringer Mannheim (Indianapolis, IN). All the SDS-PAGE reagents were obtained from Bio-Rad (Hercules, CA). The proteinase inhibitor and general chemicals (AEBSF, TPCK, TLCK, polymethylsulfonate, EDTA, EGTA, SDS, and ponceau red) were ordered from Sigma Chemical Co. (St. Louis, MO). The fluorescein diacetate, propidium iodide, and the HOECHST 33258 (bisbenzimide) were obtained from Molecular Probe (Eugene, OR). The plastic culture dish was purchased from Fisher (Houston, TX) and the German glass from Erie Scientific (Portsmouth, NH). The crystal-mount medium was obtained from Biomeda (Foster City, CA). The cell death detection ELISA Plus kit is from Hoffman-LaRoche (Basel, Switzerland). The gas-tight humidified chamber was from Billips-Rothenburg (Del Mar, CA). Enhanced chemiluminescence reagents and hyperfilm were ordered from Amersham Pharmacia (Buckinghamshire, UK). The protein assay reagents were from Pierce (Rockford, IL). The A-Sepharose beads were obtained from Sigma Chemical Co.
Recombinant human NGF, BDNF, and neurotrophin-3 were ordered from R & D Systems (Minneapolis, MN). The K252a is an alkaloid isolated from the nocardia bacteria. It inhibits ligand-dependent autophosphorylation and activation of the neurotrophin receptors Trk A, Trk B, and Trk C (concentration at which half the receptors will be blocked is 1.8 nM). In PC12 cells, K252a is a potent blocker of NGF-induced signal transduction and inhibits neurite outgrowth. 7, 19, 59 The K252a was obtained from CalBiochem (La Jolla, CA).
Antibody 203 is a rabbit polyclonal antibody that reacts with all of the Trks, but does not distinguish the different subtypes (a pan-Trk antibody). 35 It reacts across all species. It was obtained from Barbara Hempstead (Cornell University, Ithaca, NY).
Antibody 9992 is a rabbit polyclonal antibody directed against the cytoplasmic domain of the p75 receptor. It is effective against chick, rat, human, and mouse species. We obtained it from Promega (Madison, WI).
Antibodies 4G10 and PY20 are both mouse monoclonal antibodies directed against phosphotyrosine. Both specifically recognize phosphorylated tyrosine residues and do not react with phosphorylated threonine or serine residues. We obtained 4G10 from Upstate Biotechnology (Lake Placid, NY); PY20 was obtained from Transduction Laboratories (Lexington, KY).
Preparation of Cortical Neuron Cultures
Pregnant Sprague-Dawley rats with 15-to 16-day-old embryos were anesthetized with pentobarbital (100 mg/kg), and a mean of 10 to 12 fetal brains were dissected and placed into a buffer solution (HBSS with 4.2 mM bicarbonate, 1 mM pyruvate, 20 mM HEPES, and 3 mg/ml bovine serum albumin; pH 7.25). 50 After removal of the olfactory bulbs, meninges, hippocampi, basal ganglia, and brainstem, the remaining cortices were rinsed with neurobasal medium 8 and titrated through the narrow pore of a flame-constricted Pasteur pipette. The yield was 30 to 50 million fetal brain cells per female. Dissociated cells were transferred to DMEM with 10% FBS (DMEM-FBS) and seeded on a poly-D-lysine-coated 60-mm plastic culture dish or German glass culture dish. The density of the plated cells was 700/mm. 8 The cells were then maintained in a CO 2 incubator (5% CO 2 , 21% O 2 ) at 37 Ϯ 0.5˚C. 6 After 24 hours, the cells were treated for 48 hours with 5 M cytosine arabinoside in DMEM-FBS to prevent glial growth. Neurobasal medium with B-27 supplements and 0.5 mM L-glutamine was then returned. After 9 days in culture, the cells formed extensive axonal and dendritic networks and were ready for experimentation. Immunocytochemical characterization using the cell-type markers neuronspecific enolase, microtubule-associated protein-2, glial fibrillary acidic protein, myelin basic protein, and O1 (an oligodendrocytespecific marker) confirmed that the cultures were purely neuronal after 9 days (Ͼ 95%; Fig. 1 ).
Generation of Injury to the Cortical Neurons
Radiation. Neuronal cultures were exposed to ␥-radiation using a 137 Cs source (Mølsgaard Medical, Århus, Denmark) rated 2.32 Gy/ minute. Cultures were rotated during radiation to ensure uniform exposure. Radiation doses ranged from 4 to 64 Gy. After removal from the ␥-ray source, cultures were returned to the CO 2 incubator and the extent of injury was monitored at various time points. After 6 to 72 hours, cells were fixed for staining or they were lysed for protein and DNA extraction (see details later).
Hypoxia. Cultures were placed in a gas-tight humidified chamber and flushed with 5% CO 2 /95% N 2 for 3 minutes. The chamber was sealed and the cells were incubated for 3 to 24 hours at 36.5˚C. At the end of the hypoxic period, the cells were removed and returned to the standard oxygenated incubator. After 3 to 72 hours of repeated incubation, cells were prepared for analysis.
Ischemia. In vitro ischemic injury was identical to hypoxic injury, with the additional insult of incubation in a glucose-free medium. The medium was changed to a glucose-free mixture, and the cells were placed in a gas-tight humidified chamber and then flushed with 5% CO 2 /95% N 2 for 3 minutes. The chamber was sealed and the cells were incubated for 1 to 6 hours at 36.5˚C. At the end of the ischemic period, the cells were removed and returned to a standard oxygenated incubator with a glucose-containing medium. After 3 to 72 hours of repeated incubation, the cells were prepared for analysis.
Pharmacological Treatment With Protein Synthesis and RNA Transcription Inhibitors
We treated cultured neurons with 0.5 to 1 g/ml of the protein synthesis inhibitor cycloheximide or 10 to 100 ng/ml of the RNA transcription inhibitor actinomycin D. The treatment occurred 1 hour before injury with irradiation, hypoxia, or ischemia. Subsequently, cycloheximide or actinomycin D was maintained in the medium during the postinjury incubation period.
Pharmacological Treatment With NGF, BDNF, Neurotrophin-3, and K252a
The NGF, BDNF, or neurotrophin-3 at a concentration of 10 to 100 ng/ml was added to the culture medium 1 hour before injury and was maintained at the same concentration during the injury process and the subsequent incubation period. The K252a was added to the medium at a concentration of 100 nM, 30 minutes before the BDNF. This level was then maintained throughout the normal treatment process.
Morphological and Enzymatic Assessments of Cell Injury
Staining of Apoptotic Nuclei With HOECHST. A dye specific for the A-T base pair in DNA, HOECHST 33258 was used to stain cell nuclei. The cells were fixed for 12 hours in 4% paraformaldehyde at 4˚C. Cells were washed three times with PBS and stained for 5 to 10 minutes with a 1-g/ml solution of HOECHST 33258 in PBS at room temperature. After a PBS rinse and the addition of crystal-mount medium, the cells were observed and photographed on a phase-contrast and fluorescence microscope fitted with a UV2A filter.
The LDH Assay. This colorimetric assay quantifies cell injury based on the release of LDH from the cytosol of damaged cells. The magnitude of LDH efflux has been shown to correlate in a linear fashion with the extent of cell injury. 30, 40 Both the LDH in the medium (supernatant) and the LDH remaining within the cells (intracellular) were measured. By doing this, the released LDH could be normalized as a percentage of the total LDH that was within the cells before injury. Therefore, the extent of cellular injury is proportional to the LDH supernatant per cell; that is, the LDH supernatant/cell = LDH supernatant/(LDH intracellular ϩ LDH supernatant).
The media and cells were collected and centrifuged (1000 G for 5 minutes). The cells were separated from the supernatant, then lysed by sonication (10 kHz for 10 minutes). Fifty microliters of supernatant and cell lysate were separately assayed using the standard method, as previously described. 40 The DNA Fragmentation ELISA Assay. The cell death detection ELISA kit was used to quantify the binding of monoclonal antibodies against single-and double-stranded DNA or the histones H1, H2A, H2B, H3, and H4. 31 Cells were collected and lysed. Five microliters of supernatant was transferred into a streptavidin-coated cell culture plate. A mixture of antihistone-biotin and anti-DNA peroxidase was added and the resultant was incubated for 2 hours. After removal of unbound antibodies, the amount of immunoreactivity was measured using a microplate reader (model 450; Bio-Rad) at 405 nm with a reference filter of 490 nm.
Immunoprecipitation Western Blot Analyses
Prepared and treated primary cortical neurons were harvested by gentle mechanical disruption. The mixture was centrifuged at 3000 G for 5 minutes and the cells were lysed in ice-cold homogenization buffer for 30 minutes (20 mM HEPES [pH 7.6], 1 mM EDTA, 2 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonate, 50 g/ ml leupeptin, and 10 g/ml each of AEBSF, aprotinin, pepstatin, TLCK, and TPCK). The lysate was sheared 15 times through a 1-ml syringe with a 25-gauge needle. The protein concentration was determined by the protein assay.
The extracted protein (100-500 g) was incubated for 2 hours with the primary antibodies at 4˚C and for an additional hour with a 1:1 slurry of protein A-Sepharose. The A-Sepharose beads were centrifuged at 15,000 G for 4 minutes and washed three times with lysis buffer. After the final wash, the beads were boiled for 10 minutes with 30 to 40 l gel loading buffer (0.25 M Tris [pH 6.8]), 0.2 M dithiothreitol, 8% SDS, 0.02% bromophenol blue, and 20% glycerol). The samples were then transferred to an SDS-PAGE.
Samples were resolved in a vertical electrophoresis chamber by using a 4% stacking gel over a 7.5% acrylamide resolving gel for 1 hour at 200 V. Separated proteins were laterally transferred to nitrocellulose membranes (0.45 M) by using a transfer buffer consisting of 0.192 M glycine and 0.025 M Tris (pH 8.3) with 10% methanol at a constant voltage (100 V) for 1 hour at 4˚C. These immunoblots were blocked for 112 hours in 5% nonfat milk in 20 mM Tris, 0.15 M NaCl, and 0.005% Tween 20 at 4˚C. Incubation with the primary antibodies was performed for 12 hours at 4˚C by using the same buffer (5% nonfat milk in 20 mM Tris, 0.15 M NaCl, and 0.005% Tween 20) . The immunoreactive protein bands were detected by enhanced chemiluminescence.
Statistical Analysis
Each experiment involving LDH release and DNA fragmentation ELISA involved six cell plates. The contents of all these cell plates were combined for analysis. Each experiment was performed three times and group means and SDs were calculated. Comparisons between groups were made using analysis of variance with a post hoc Fisher test. A commercially available statistical program was used (GraphPad Prism, version 2.01; GraphPad Software, Inc., San Diego, CA). Values are given as the means Ϯ SD. Differences were considered significant at a probability value less than or equal to 0.05. Data from the staining experiments (fluorescein diacetate, propidium iodide, and HOECHST) and the Western blots were qualitative, and statistical analyses were not performed.
Results
Release of LDH Quantifies Cell Injury in a Dose-and Time-Dependent Manner
Dose-response assays were performed to determine the levels of injury to be used in subsequent experiments. Exposure of cortical neuron cultures to 8, 16, 32, and 64 Gy of ␥-rays induced a dose-dependent increase in LDH at 24 hours postinjury. The LDH released was 15.4% for the control, 18.5% for cells exposed to 8 Gy, 24.4% for 16 Gy, 33.6% for 32 Gy, and 43.2% for 64 Gy. The difference was statistically significant for doses of 16 Gy or higher. Following exposure to 32 Gy, the rise in LDH at various time points was determined. At 6, 24, 48, and 72 hours after irradiation, the percentage of LDH released into the medium was 23.1, 33.6, 34, and 32.7%, respectively. The difference became statistically significant at 24 hours. A 32-Gy dose followed by 24 hours of incubation was used for subsequent experiments.
Exposure of cortical neuron cultures to 3, 6, and 24 hours of hypoxia was followed by 24 hours of reoxygenation. The release of LDH for these hypoxia periods was 25.6, 39.6, and 47.3%, respectively. All differences were statistically significant. After 6 hours of hypoxia followed by reoxygenation, the rise in LDH was determined for 3, 6, 24, and 72 hours later: 22.3, 24.2, 39.6, and 35.6%, respectively. All differences were statistically significant. For subsequent experiments, 6 hours of hypoxia followed by 24 hours of reoxygenation was used as the standard.
Exposure of cortical neurons to 1, 3, and 6 hours of ischemia was followed by a 24-hour period of normal culture conditions. With these conditions, released LDH was 46.9, 50.1, and 53.6%, respectively. The differences were statistically significant for all doses. The level of injury was quite dramatic, and the lowest dose indicated the maximal response. Following exposure to 1 hour of ischemia, the rise in LDH at various time points was determined. At 3, 6, 24, 48, and 72 hours following injury, the percentage of LDH release was 35.9, 40.1, 46.9, 47.2, and 47.1%, respectively. All were statistically significant differences. For subsequent experiments, a dose of 1 hour of ischemia followed by 24 hours of normal culture conditions was used as the standard.
The temporal pattern of injury was different depending on the noxious stimuli. Following ischemia, the maximal injury occurred within 3 hours. With irradiation and hypoxia, the maximal injury occurred 24 hours before maximal LDH release.
Cell Death
Staining With HOECHST. Figure 2A reveals normal controls with staining of the nuclei. Figure 2B demonstrates neurons 24 hours following irradiation with 32-Gy doses. Notice the multiple apoptotic bodies (large arrow) and the chromatin condensation (small arrow). Figure 2C reveals neurons 24 hours following ischemia. Round nuclei devoid of apoptotic bodies also appear. Following hypoxia, apoptotic bodies are visible, but at a lower density compared with irradiated cells (Fig. 2D) .
Measuring Fragmented DNA by ELISA. The average absorbance, which corresponds to the amount of fragmented DNA, was noted 24 hours following radiation, hypoxia, or ischemia. The absorbance of uninjured controls was 0.296. Following ischemia, absorbance was 0.312 (not statistically significantly different). Following irradiation, absorbance increased to 0.632 (p Ͻ 0.001). Following hypoxia, the absorbance was 0.433 (p Ͻ 0.001). These data indicate predominant death by apoptosis following irradiation, by necrosis following ischemia, and a mixed response following hypoxia.
Protein Synthesis and RNA Transcription Inhibitors. Because apoptosis is an active process requiring gene transcription and protein translation, both protein synthesis and transcription inhibitors have been reported to diminish apoptotic death. Figure 3 . Note that NGF has no effect on LDH release, whereas BDNF and neurotrophin-3 confer significant, dose-dependent protection from radiation injury. ng/ml of actinomycin D. Following irradiation, both inhibitors induced a significant decrease in LDH release (p Ͻ 0.001). Similar, though less robust, results were noted following hypoxia. These were statistically significant differences. As expected, neither inhibitor caused any effect following ischemia.
Protection of Neurons from Cell Death Following Injury
Different doses of the neurotrophins (0.1-100 ng/ml) were administered 1 hour prior to the application of 32 Gy radiation. The percentage of released LDH was measured 24 hours later. Both BDNF and neurotrophin-3, but not NGF, protected the neurons in a dose-dependent manner. Significant decreases in released LDH were noted following treatment with BDNF and neurotrophin-3 only (100 ng/ml; Fig. 4 ). In fact, the percentage of released LDH decreased from 38.9% (in untreated controls) to 18.65 and 17.56% in cells treated with BDNF and neurotrophin-3, respectively (p Ͻ 0.001 for both groups). Following NGF treatment at the same dose (100 ng/ml), 37.6% of LDH was released (Fig. 5A) . Identical results were obtained with a different marker for cell injury; DNA fragmentation ELISA only measures apoptotic death. Both BDNF and neurotrophin-3, but not NGF, diminished apoptotic cell death (Fig. 5B) .
Following hypoxic injury, similar though less robust protection was noted. The administration of 100 ng/ml BDNF and neurotrophin-3 reduced the amount of LDH released to 29.3 and 31%, respectively, from a baseline of 36.7% (p Ͻ 0.05). Again, NGF did not have an effect and the LDH released was 36.2% (Fig. 6A) . As with the application of radiation, the DNA fragmentation ELISA revealed decreases with BDNF and neurotrophin-3 treatment (Fig. 6B) .
With ischemic injury, however, no protective response occurred with any neurotrophin treatment. Figure 7A tent of injury; that is, the LDH released was 51.2, 49.7, and 49.3%, respectively (no significant difference). Figure 7B shows the absorbance levels following DNA fragmentation ELISA. The difference before and after injury was small and not statistically significant. This was expected since cell death occurs predominantly by necrosis following ischemia in this model. Again, the neurotrophins had no effect on DNA fragmentation.
These data indicate that BDNF and neurotrophin-3 protect against apoptotic, but not necrotic, cell death. The most robust response occurred following radiation, which induces mostly apoptotic death in the injured cells. A less robust response occurred with hypoxia, which induces a mixture of apoptotic and necrotic death. 39 No response occurred following ischemia, which induces only necrotic death.
Tyrosine Kinase Receptors B and C Are Expressed in Primary Cortical Neurons
To assess the expression of the Trk and p75 receptor in this model, we performed immunoprecipitation and Western blots with antibody 203 (an anti-pan-Trk antibody) and antibody 9992 (an anti-p75 antibody). Cells were harvested on culture days 0, 2, 3, 6, 8, and 10; the protein was extracted and probed for the Trks and p75. Figure 8 features results of the Western blotting for antibody 203. No Trk expression was noted initially, but then it gradually increased until it was quite robust by Day 8. This result correlates with the maturation of neurons and the development of extensive axonal and dendritic networks. Note that all subsequent experiments were done at precisely 9 days in culture, to ensure uniformity in Trk expression. For p75, however, no receptor expression was noted at any time following culture. The results of Western blotting are featured in Fig. 9 . Although there is a faint band at the p75 size, the intensity is equal to or less than the other bands that represent nonspecific background staining. Therefore, we believe that the primary cortical neurons express the Trks but not p75.
To determine the specific Trks that were being expressed, we used two antibodies directed against phosphotyrosine, 4G10 and PY20. Phosphotyrosine is only produced when the Trk is stimulated by the appropriate ligand. Therefore, phosphotyrosine will appear after treatment with a ligand (such as BDNF) only if the appropriate receptor exists (such as Trk B).
After 9 days in culture, the neurons were incubated with NGF, BDNF, or neurotrophin-3. Protein was extracted and Western blot analyses were performed using 4G10 and PY20. Positive phosphotyrosine bands were noted (at the appropriate Trk protein size) following treatment with BDNF and neurotrophin-3, but not NGF (Fig. 10) . These results indicate directly that only BDNF and neurotrophin-3 were able to stimulate the appropriate Trks and indirectly that a functional Trk B and Trk C are present, but not a functional Trk A. This explains the differences in treatment effects noted with the various neurotrophins. Note that the NGF treatment had no effect given that the cells did not express the functional receptor.
Protective Effects of BDNF and Neurotrophin-3 by Signaling Through the Trk
To determine that the neurotrophin effect required Trk activation, we used K252a, a microbial alkaloid that can inhibit receptor tyrosine kinases such as the Trks. Notice in Fig. 10 that no phosphotyrosine is demonstrated when BDNF or neurotrophin-3 treatment occurs in the presence of K252a. This indicates the inhibition of the Trk activation following BDNF or neurotrophin-3 binding. When tested with injury, the inhibition of the Trks completely abolished the protective effects of the neurotrophins. Western blots demonstrating the expression of the p75 receptor in primary cortical neurons. Cells were harvested on Days 0 through 10 following culture, the protein was extracted, and p75 expression was detected on Western blotting by using antibody 9992. No expression of the p75 receptor was noted (the bands represent nonspecific background). Figure 11 shows the effect of K252a when given in conjunction with the neurotrophins following irradiation (32 Gy). The K252a (100 nM) was added 30 minutes before NGF, BDNF, or neurotrophin-3 and was kept in the medium during irradiation. After 24 hours of repeated incubation, LDH released into the medium was measured. The K252a alone had no effect. Following the application of radiation, the LDH released was 37.2%. With K252a in the medium, the LDH released was identical at 37.9%. The K252a completely blocked the treatment effect of BDNF and neurotrophin-3, however. The BDNF treatment alone, without K252a, produced an LDH release of 24.6%. The BDNF treatment with K252a caused an LDH release of 37.3%. Similar findings were noted with neurotrophin-3. Again, NGF did not have an effect, with or without K252a. Figure 12 features the absorbance values following DNA fragmentation ELISA. The BDNF treatment decreased DNA fragmentation, showing an absorbance of 0.436 (a statistically significant difference). Combined with K252a it produced an absorbance of 0.642. In sum, these data indicate that the Trk must be activated for the neurotrophins to exert a protective effect.
Discussion
In this report, we detail an in vitro model for central nervous system injury in which neurons can be induced to die by apoptosis or necrosis, depending on the noxious stimuli. Following the application of radiation, cells died by apoptosis. Morphological assays revealed chromatin condensation and the presence of apoptotic bodies. Results of the ELISA showed DNA fragmentation. Cell death was delayed by at least 6 hours and could be inhibited by stopping macromolecular synthesis. These are classic characteristics of apoptotic death. Because this process was delayed, its prevention may be amenable to pharmacological interventions following injury; that is, there may be a window for treatment.
Following ischemia, the cells died by necrosis. The dying cells were swollen and enlarged and appeared immediately. Cell death occurred by 30 minutes and could not be reduced by RNA transcription or protein synthesis inhibitors. Apoptotic bodies could not be visualized, and DNA fragmentation assays did not show a difference compared with controls. Hypoxia produced a mixture of the two fatal processes.
When the neurotrophins were tested in this model, we noted powerful protection in situations in which apoptosis plays a significant role (in this case, following radiation and hypoxia). The neurotrophins, however, did not affect necrosis. In addition, we found that activation and signaling through the Trk is a requirement for the neurotrophin effect. Because the primary cortical neurons did not express a functional Trk A, NGF did not have a therapeutic effect. Neither BDNF nor neurotrophin-3, however, could activate functional receptors and induce a robust response. By inhibiting the Trk signaling cascade with K252a, the protective effect was blocked.
These findings have significant implications for the clinical use of neurotrophins. First, they should be tested only in disorders in which apoptosis is a major process. Where necrosis predominates, the neurotrophins would likely have no effect. Second, the activation of the Trk signaling cascade is necessary. 58 Although the expression of the Trks is high during early human development, it is more limited or even absent in the adult. Investigators using monoclonal antibodies to Trk A in adult rodents revealed some expression in the basal forebrain and the basal ganglia, but no expression in the rest of the central nervous system. 18 Other studies featuring different techniques have demonstrated similar results for the Trks as well as p75. 21, 49, 55 Therefore, neurotrophin treatment in adults may be limited by the lack of receptor availability, and other strategies for the activation of the Trk signaling cascade must be investigated. Perhaps neurotrophin treatment is most applicable to the pediatric population, particularly following radiation injury.
Conclusions
In this report we detail an in vitro model of injury by using rat primary cortical neurons. With the application of various noxious stimuli, including radiation and ischemia, the cells can be induced to die by apoptosis, necrosis, or both processes. The therapeutic potential of the neurotrophins NGF, BDNF, and neurotrophin-3 were tested. We FIG. 11 . Bar graph exhibiting the effect of K252a on NGF, BDNF, and neurotrophin-3 treatment following irradiation. The K252a (100 nM) was added 30 minutes before NGF, BDNF, or neurotrophin-3 and kept in the medium during irradiation (32 Gy). After 24 hours of repeated incubation, the percentage of released LDH was measured. The K252a completely blocked the protective effect of both BDNF and neurotrophin-3. Error bars represent the SD. ***p , 0.001.
FIG. 12.
Bar graph demonstrating the effect of K252a on BDNF treatment following irradiation as measured on DNA fragmentation ELISA. The K252a (100 nM) was added 30 minutes before BDNF and kept in the medium during irradiation (32 Gy). After 24 hours of repeated incubation, ELISA was performed and absorbance was measured. The K252a completely blocked the effect of BDNF. Error bars represent the SD. **p , 0.01, and ***p , 0.001.
